Holen Sie sich die Stockscreener-App
70.07
0.54%
0.39
Handel nachbörslich:
70.07
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$69.68
Offen:
$70.09
24-Stunden-Volumen:
4.25M
Relative Volume:
0.84
Marktkapitalisierung:
$228.90B
Einnahmen:
$54.98B
Nettoeinkommen (Verlust:
$7.77B
KGV:
28.14
EPS:
2.49
Netto-Cashflow:
$9.14B
1W Leistung:
-1.00%
1M Leistung:
-0.50%
6M Leistung:
+5.31%
1J Leistung:
-11.41%
1-Tages-Spanne:
$69.66
$70.37
1-Wochen-Bereich:
$69.65
$71.14
52-Wochen-Spanne:
$61.24
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Firmenname
Astrazeneca PLC
Sektor
Branche
Telefon
44 20 3749 5000
Adresse
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Vergleichen Sie AZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
70.07 | 228.90B | 54.98B | 7.77B | 9.14B | 2.49 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
AstraZeneca (NASDAQ:AZN) PLC Stock Sees Institutional Growth on Nasdaq Composite - Kalkine Media
AstraZeneca and GSK fall after Trump renews pharma tariff threat - Proactive Investors
FTSE 100 Live: Stocks drop and oil spikes as Iran 'will not surrender', AstraZeneca falls on tariff threat - Proactive Investors
FTSE 100 Live: Stocks drop into the red, AstraZeneca and GSK fall on Trump tariff threat - Proactive Investors
AstraZeneca, GSK shares down after Trump threatens drug import tariffs By Investing.com - Investing.com Nigeria
FTSE 100 Live: Stocks edge higher as UK inflation eases, AstraZeneca and GSK fall - Proactive Investors
FTSE 100 Live: Stocks open higher as UK inflation eases, AstraZeneca and GSK fall - Proactive Investors
Astrazeneca makes $5.3B drug R&D pact with CSPC - BioWorld MedTech
AstraZeneca (AZN) Faces Potential Changes in Drug Advertising Ru - GuruFocus
Levi & Korsinsky Reminds AstraZeneca PLC Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025AZN - ACCESS Newswire
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer - Insider Monkey
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
Sector Update: Health Care Stocks Slide Late Afternoon - MarketScreener
AstraZeneca Inks Up To $5.3B AI Drug Deal With Chinese Firm - Law360
FIVE AT FIVE: FTSE 100 unsettled by Israel strike; AstraZeneca strikes $3.6bn Chinese AI deal - Proactive financial news
AstraZeneca and CSPC partner on AI drug research By Investing.com - Investing.com Nigeria
AstraZeneca and CSPC partner on AI drug research - Investing.com
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal - Pharmaceutical Technology
AstraZeneca, CSPC Pharmaceuticals Enter Research Agreement - marketscreener.com
AstraZeneca signs research agreement with China's CSPC (AZN) - Seeking Alpha
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans - BioPharma Dive
AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance - insights.citeline.com
AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 BillionAstraZeneca (NASDAQ:AZN) - Benzinga
AstraZeneca, Chinese bio firm sign $5.2B drug deal - breakingthenews.net
AstraZeneca signs $5.2bn deal to develop drugs for chronic disease with Chinese biotech - Financial Times
AstraZeneca Signs Nearly $5.3 Bln AI-enabled Research Deal With China's CSPC Pharma - Nasdaq
AstraZeneca (AZN) Enters Collaboration with CSPC for Novel Thera - GuruFocus
AstraZeneca: R&D agreement with CSPC Pharmaceuticals Group - MarketScreener
AstraZeneca bets big on AI and China with $3.6bn CSPC collaboration - Proactive financial news
AstraZeneca Enters Strategic Collaboration with CSPC Pharmaceuticals Group Limited - marketscreener.com
AstraZeneca, CSPC Ink Strategic Research Collaboration for AI-Driven Drug Discovery - marketscreener.com
The Zacks Analyst Blog Highlights Microsoft, AstraZeneca and BlackRock, Taylor Devices and Geospace Technologies - TradingView
AstraZeneca partners with CSPC in deal worth up to $5.33 billion - Investing.com Nigeria
AstraZeneca forms $5.3 billion AI drug discovery deal with CSPC - Investing.com
AstraZeneca signs AI research deal with China's CSPC for chronic diseases - MarketScreener
AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC - Yahoo Finance
Astrazeneca Enters Collaboration Worth Up To $5.22 Bln With CSPC Pharmaceuticals - marketscreener.com
Top Stock Reports for Microsoft, AstraZeneca & BlackRock - Yahoo Finance
Chancery Tags AstraZeneca Unit For $180M 'Expectation' Loss - Law360
Leading bank sees AstraZeneca upside seen in hypertension drug, tempers lung cancer hopes - Proactive financial news
AstraZeneca CFO Donates Shares to Charity - TipRanks
AstraZeneca CFO donates shares to charity - Investing.com
AstraZeneca CFO donates shares to charity By Investing.com - Investing.com UK
REGAstraZeneca PLCDirector/PDMR Shareholding - TradingView
AstraZeneca (AZN): Vaccine Advisory Panel Reshuffled, Impact on Pharma Stocks | AZN Stock News - GuruFocus
UBS bullish on AstraZeneca’s baxdrostat, cautious on AVANZAR By Investing.com - Investing.com Nigeria
At a bargain-basement valuation now, is AstraZeneca’s share price impossible for me to ignore? - Yahoo
AstraZeneca (AZN) Watches CDC Vaccine Policy Developments | AZN Stock News - GuruFocus
AstraZeneca Unit Owes $180 Million-Plus in Syntimmune Case (1) - Bloomberg Law News
AstraZeneca, Lilly & J&J: Strategic Moves Powering SGLT‐2 - openPR.com
Finanzdaten der Astrazeneca PLC-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):